Dual targeting of EGFR and ERBB2 pathways produces a synergistic effect on cancer cell proliferation and migration in vitro. (27th May 2016)

• Record Type: Journal Article
• Authors: Gray, M. E.; Lee, S.; McDowell, A. L.; Erskine, M.; Loh, Q. T. M.; Grice, O.; Argyle, D. J.; Bergkvist, G. T.
• Is Part Of: Veterinary and comparative oncology. Volume 15:Number 3(2017:Sep.)
• Page Start: 890
• Page End: 909
• Publication Date: 2016-05-27
• Subjects: cell signalling -- comparative oncology -- gene therapy -- in vitro models -- small animal -- tumour biology -- tyrosine kinase; Veterinary oncology -- Periodicals; Neoplasms -- veterinary -- Periodicals; 636.0896994005
• DOI: 10.1111/vco.12230
• Languages: English
• ISSNs: 1476-5810

Abstract

Abstract: Members of the epidermal growth factor receptor (EGFR/ERBB) gene family are frequently dysregulated in a range of human cancers, and therapeutics targeting these proteins are in clinical use. We hypothesized that similar pathways are involved in feline and canine tumours and that the same drugs may be of clinical use in veterinary patients. We investigated EGFR and ERBB2 targeting using a panel of feline and canine cell lines. EGFR and ERBB2 were targeted with siRNAs or tyrosine kinase inhibitors (TKIs) and their effect on cellular proliferation, colony formation and migration was investigated in vitro . Here we report that EGFR and ERBB2 combined siRNA targeting produced synergistic effects in feline and canine cell lines similar to that reported in human cell lines. We conclude that dual EGFR and ERBB2 targeting using TKIs should be further evaluated as a potential new therapeutic strategy in feline head and neck and mammary tumours and canine mammary tumours.